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Dengue infection is a mosquito-borne viral disease which is in emerging trend and major health problem in our country as well as worldwide. The World Health 
Organization (WHO) estimates that about two-fifths of the world 
population are at risk for this dengue infection [1]. There are four 
serotypes of dengue virus causing dengue without warning sign, 
dengue with warning sign, and severe dengue according to the 
WHO 2009 guidelines [2]. Recovery from infection with one 
serotype offers lasting immunity against that individual serotype; 
however, future infections with different serotypes increase the 
danger of developing severe dengue [3,4]. In India, the annual 
incidence is estimated to be 7.5–32.5 million [5]. In Odisha, a state 
of Eastern India, the first outbreak was reported in 2010, followed 
by extensive outbreaks in 2011, affecting large populations. Risk 
of mortality in treated cases is <1% while mortality rate among 
untreated cases escalates to 20% [6].
Unusual manifestations involving liver and central nervous 
system in dengue infection have been reported [7,8]. Severity 
of hepatic dysfunction in youngster with dengue infection 
ranges from milder form of injury with rise of transaminases 
to severe form with jaundice and liver failure [9]. Mechanisms 
of liver injury in dengue may be due to direct effects of the 
virus or host immune response on liver cells, circulatory 
compromise, metabolic acidosis, and/or hypoxia caused by 
hypotension or localized vascular leakage inside the liver [10]. 
The incidence of hepatic dysfunction is more in severe dengue 
and dengue with warning signs [11]. Aminotransferase levels 
are useful in predicting the occurrence of hepatic dysfunction 
and spontaneous bleeding [12]. As per the studies among 
Indian subcontinent, the most promising cause of acute hepatic 
failure in children with dengue infections varies from 18.5% 
to 34.3% [13]. Although the liver is not the major target 
organ, changes such as centrilobular necrosis, fatty change, 
Kupffer cells hyperplasia, acidophilic bodies, and monocytic 
infiltration of portal tracts have been reported in patients with 
dengue [14,15].
In spite of an established severity score for dengue fever [16] 
as well as grading system for hepatic dysfunction [17], till date, 
there is no such dengue severity score based on the hepatic 
dysfunction, i.e., laboratory as well as clinical hepatic parameters. 
Hence, the current objective of our study is to develop a new 
severity score system “dengue hepatic severity score” (DHSS) 
basing on the above hepatic parameters to strengthen our existing 
healthcare system at the periphery level.
ABSTRACT
Introduction: Recent studies from India and Thailand show that dengue infection was the most compelling cause of acute hepatic 
failure in children contributing to 18.5% and 34.3%, respectively, and till now, there is no proper dengue severity score based 
on the hepatic dysfunction, i.e. laboratory as well as clinical hepatic parameters. Objective: The objective of this study was to 
develop a new dengue hepatic severity score (DHSS) based on only hepatic dysfunction parameters. Methods: The present cross-
sectional analytical study was conducted in the Department of Paediatrics, Burla, Sambalpur, Odisha, from November 2015 to 
October 2017 after getting the institutional ethical clearance. A total of 76 cases selected as per predefined inclusion and exclusion 
criteria, categorized into three groups after taking written informed consent of their legal hare. Relevant hepatic parameters (both 
clinical and laboratory) were collected, and data were finally analyzed using receiver operating characteristic curve to get a cutoff 
value for each group. Results: The cutoff value of DHSS of ≥7 between Group 1 and Group 2 evidenced by area under the curve 
(AUC)=99.6% with 95% confidence interval (CI) (95.6–100%), sensitivity - 100%, specificity - 94.6%, and a cutoff ≥18 between 
Groups 2 and 3 exhibited by AUC=100% with 95% CI (94.6–100%), sensitivity - 100%, and specificity - 94.6%. Hence, the DHSS 
is formulated as ≤6 (no severe hepatic dysfunction), 7–17 (severe), and ≥18 (very severe). Mean duration of hospitalization in 
days between three groups of hepatic dysfunction was statistically significant as evidenced by one-way ANOVA; F (2, 73)=19.83, 
p=0.000. Conclusion: DHSS system will help the primary health caregiver for triaging, early recognition, and prompt management 
to prevent additional deterioration.
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METHODS
This present observational analytical cross-sectional study was 
conducted at OPD/IPD of the Department of Paediatrics, Veer 
Surendra Sai Institute of Medical Sciences and Research, Burla, 
Sambalpur, a 750 bedded tertiary care hospital of western Odisha 
from November 2015 to October 2017 after getting approval from 
the Institutional Research and Ethics Committee (VIREC).
Of this 2-year study period, the first 1 year was dedicated 
for data collections and subsequent year for data analysis and 
interpretations. Based on a previous study done in 2010 [15], the 
prevalence of deranged liver function tests (LFTs), i.e., raised 
aspartate transaminases (ASTs) and alanine aminotransferase 
(ALT) in dengue infection was 97%. Minimum sample size 
calculated was 70 using n-Master v2 by single proportion 
absolute precision method taking proportion as 0.97, absolute 
precision of 4%, and confidence interval (CI) of 95%. Due to 
less number of cases, we have also included cases retrospectively 
from our hospital records from November 2013 to October 2015. 
Inclusion criteria were 1–14-year-old child seropositive for NS1 
antigen and/or IgM antibody, whereas exclusion criteria were 
the presence of any severe preexisting morbidities (congenital 
heart disease [CHD], severe malnutrition, and developmental 
delay), child with coexisting malaria or enteric fever or viral 
hepatitis or drug-induced hepatitis. A total of 92 cases selected 
as per inclusion criteria, out of which 7 did not give consent and 
9 excluded as per exclusion criteria. 76 cases were enrolled as 
study participants after giving informed consent (Fig. 1). All 
the children between 1 and 14 years of age seropositive for 
dengue NS1/IgM [18] attending to our OPD/IPD were taken by 
simple consecutive sampling method. All confirmed cases were 
categorized according to the WHO 2009 criteria [2]. As this was 
a hospital-based study, the study population and target population 
were same, i.e., the children who were satisfying the inclusion 
criteria.
All the routine investigations as well as LFT were done 
for each patient. Dengue serology (NS 1/IgM) was done 
using ELISA method in MERILYSER-EIA QUANT-EIA 
WASH. Complete blood count (CBC) was done in automated 
hematology analyser-HORIBA-ES60 by electrical impedance 
and photometry method. LFT was done in TRANSASIA by 
spectrophotometry technique. Serum (Sr.) electrolytes were 
done in by agarose gel electrophoresis and immunofixation 
method. Renal function tests (RFTs) were performed in 
TRANSULIA-CHEM-7 by kinetic method. Prothrombin time-
international normalized ratio (PT-INR) was investigated in 
AGAPEE-CD504-08 by electromechanical clot detection 
technique. Sr. albumin was done by nephelometry method in 
TRANSULIA-CHEM-7. Bleeding time (BT) and clotting time 
(CT) were done by Lee and White method manually. Random 
blood sugar (RBS) was done in TRANSULIA-CHEM-7 by end-
point technique.
We have calculated the cutoff value of each laboratory 
parameters for hepatic dysfunction (blood sugar, Sr. albumin, 
AST, ALT, alkaline phosphatase [ALP], Sr. bilirubin total and 
direct, PT/INR, CT, Sr. potassium [K] and sodium [Na], and Sr. 
urea and creatinine) by applying receiver operating characteristic 
(ROC) curve for each type of dengue. Among the above laboratory 
parameters, those have acceptable cutoff values as per ROC curve 
analysis were taken into account for scoring and basing on that 
we have given a score/number to each category (i.e., 0, 1, and 2). 
Then, a clinical manifestation of hepatic dysfunction was given 
a score of 0 (absent) and 1 (present). Laboratory parameter of 
hepatic dysfunction was taken as Score-A, whereas Score-B was 
for clinical hepatic manifestations score. Laboratory parameters 
of hepatic dysfunction variables (Score-A) were Sr. bilirubin 
total and direct, AST, ALT, ALP, CT, and PT-INR. Clinical 
hepatic manifestations variables (Score-B) comprises vomiting, 
abdominal pain and/or tenderness, hepatomegaly, ascites, loss 
of consciousness or seizure, bleeding manifestations (petechiae, 
purpura, ecchymosis, gum bleeding, epistaxis, hematemesis, 
GI bleed, hematochezia, and melena), respiratory distress, and 
shock (Table 1a). Final score, i.e., DHSS was calculated based 
on the score of laboratory parameters of hepatic dysfunction plus 
clinical hepatic manifestations scores. After getting a score for 
each category, we again calculated a cutoff value for each type of 
Figure 1: Study flow diagram
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dengue by applying ROC curve. Then, hepatic severity score for 
dengue children was derived and categorized into three varieties, 
i.e., no severe, severe, and very severe hepatic dysfunction basing 
on the cutoff score.
Each patient was enrolled in the study after taking informed 
written consent from the parent or the legal guardian. Case report 
forms for each patient was filled, and data were collected in 
EpiData v 4.2.0 software regarding the baseline characteristics 
such as age, sex as confounders, and other relevant investigations 
such as LFT, electrolytes, CT, and RFT. Confidentiality of the 
data was well maintained. No part of the data was given to 
any open access. Data checking was done manually by both 
principal investigator (PI) and co-PI. Double data entries were 
done by PI and co-PI separately. Data validation was done by 
computer-assisted software EpiData v 4.2.0. Data normalcy was 
tested using Shapiro–Wilk and Kolmogorov–Smirnov test where 
p>0.05 were considered to be of normally distributed data. Non-
normal data were subjected to transformation statistics (right-
skewed or left-skewed data were subjected to square root and 
square transformation, respectively). Intergroup variabilities of 
continuous data were analyzed with one-way ANOVA and for 
categorical data with Pearson’s Chi-square tests. ROC curve 
analysis was performed using SPSS v24 (IBM, New York, USA) 
and Dxt v 1.0 (BRTC, Bagayam, Vellore) software, and then, 
results were interpreted.
RESULTS
Among 76 serologically confirmed dengue patients (M:F=1.45:1), 
49% (37) were from Group 1, 27% (21) from Group 2, and 24% 
(18) were from Group 3. Of 37 dengue children of Group 1, 16.2% 
(6) were treated on OPD basis. There is no statistically significant 
difference of mean age in years between Group 1 (7.66 ± 2.92), 
Group 2 (7.77 ± 3.18), and Group 3 (7.47 ± 2.85) as determined 
by F (2)=0.048, p=0.953. There is no statistically significant 
difference in sex distribution among three groups as defined by 
Pearson’s Chi-square (2)=0.918, p=0.632 and Cramer’s V=0.110, 
p=0.632. The most common symptom was fever (100%) 
followed by vomiting (65.8%) and least common was bleeding 
manifestations (22.4%). The most common sign was abdominal 
tenderness (50%) and hepatomegaly (50%). 37% (28) were NS1 
positive and 72% (55) were IgM positive. The total percentage of 
dengue serology positive was more than 100% as some patients 
had multiple seropositive status.
All LFT parameters as well as Sr. electrolytes, RFT and RBS 
were taken into consideration, and cutoff value was calculated by 
applying ROC curve (Tables 2a and b).
The cutoff value of DHSS was ≥7 between Group 1 and 
Group 2 as evidenced by ROC curve having area under the curve 
(AUC)=99.6% with 95% CI (95.6-100%), sensitivity - 100%, 
specificity - 94.6%, positive likelihood ratio=18.5, and negative 
likelihood ratio=0 (Fig. 2). It implied the odds of DHSS increased 
to 18.5-fold for children with severe hepatic dysfunction as 
compared to no severe hepatic dysfunction and there is high 
probability that children with dengue will fall into severe hepatic 
dysfunction once they achieved the cutoff score of 7.
DHSS has a cutoff value of ≥18 among Groups 2 and 3 dengue 
children as exhibited by AUC=100% with 95% CI (94.6–100%), 
sensitivity - 100%, specificity - 94.6%, positive likelihood 
ratio=214,680, and negative likelihood ratio=0 (Fig. 3), which 
signifies that there is very less probability, i.e., 214,680 times less 
chance for dengue children with very severe hepatic dysfunction 
will fall into severe hepatic dysfunction category, whereas there 
is high probability that the children with dengue will fall into 
very severe hepatic dysfunction once they achieved the cutoff 
score of 18. Hence, the cutoff score for dengue hepatic severity is 
formulated as ≤6 (no severe hepatic dysfunction), 7–17 (severe), 
and ≥18 (very severe) (Table 1b).
There was statistically significant difference of mean score 
between three categories of hepatic dysfunction as evidenced 
by one-way ANOVA; F (2.73)=660.351, p=0.000. Mean score 
of no severe hepatic dysfunction (2.92 ± 1.92) was significantly 
lower as compared to very severe hepatic dysfunction (21.28 ± 
1.23) and severe hepatic dysfunction (10.48 ± 1.86) as evidenced 
by Tukey post hoc, p=0.000. Mean score of very severe 
hepatic dysfunction (21.28 ± 1.23) was significantly higher 
as compared to severe hepatic dysfunction (10.48 ± 1.86) and 
no severe hepatic dysfunction (2.92 ± 1.92) as evidenced by 
Table 1a: Score‑B (clinical parameters)
Variables Absent Present
Vomiting 0 1
Abdominal pain/tenderness 0 1
Hepatomegaly 0 1
Ascites 0 1
Severe bleeding 0 1
Respiratory distress 0 1
Shock 0 1
Loss of consciousness/seizure 0 1
Table 1b: Final score (dengue hepatic severity score) = 
Score‑A+Score‑B (Maximum score=22)
Categories Score
No severe hepatic dysfunction ≤6
Severe hepatic dysfunction 7–17
Very Severe hepatic dysfunction ≥18
Table 1c: Score‑A (Laboratory parameters)
Variables Cutoff values in each score
0 1 2
Serum bilirubin total (mg/dl) ˂0.9 0.9–3.69 ≥3.7
Serum bilirubin direct (mg/dl) ˂0.37 0.37–1.079 ≥1.08
AST (IU/L) ˂85 85–140 ≥141
ALT (IU/L) ˂99 99–171 ≥172
ALP (IU/L) ˂193 193–380 ≥380
Clotting time (min) ˂5.0 5.0–7.9 ≥8.0
PT-INR ˂1.19 1.19–1.53 ≥1.54
ASTs: Aspartate transaminases, ALT: Alanine aminotransferase, ALP: Alkaline 
phosphatase, PT‑INR: Prothrombin time‑international normalized ratio
Murmu et al. Dengue hepatic severity score in children
Vol 5 | Issue 2 | Feb 2018 Indian J Child Health 83
Tukey post hoc analysis, p=0.000; whereas mean score of severe 
hepatic dysfunction (10.48 ± 1.86) is significantly lower than 
very severe hepatic dysfunction (21.28 ± 1.23) but higher than no 
severe hepatic dysfunction (2.92 ± 1.92) as evidenced by Tukey 
post hoc, p=0.000.
There was statistically significant difference of mean duration 
of hospitalization in days between three groups of hepatic 
dysfunction as evidenced by one-way ANOVA; F=(2, 73)=19.83, 
p=0.000. Mean duration of hospitalization in days in no severe 
hepatic dysfunction (1.68 ± 1.07) was significantly lower as 
compared to very severe hepatic dysfunction (2.72 ± 1.96) and 
severe hepatic dysfunction (4.00 ± 1.20) as evidenced by Tukey 
post hoc, p=0.000. Mean duration of hospitalization in days in 
severe hepatic dysfunction (4.09 ± 1.22) was significantly higher 
as compared to no severe hepatic dysfunction (1.68 ± 1.07) and 
very severe hepatic dysfunction (2.72 ± 1.96) as evidenced by 
Tukey post hoc analysis, p=0.029; whereas mean duration of 
hospitalization in days in very severe hepatic dysfunction (2.72 ± 
1.96) is significantly lower than severe hepatic dysfunction (4.00 
± 1.20) but higher than no severe hepatic dysfunction (1.68 ± 
1.07) as evidenced by Tukey post hoc, p=0.011.
DISCUSSIONS
Dengue is a major international health concern prevailing in 
tropical and subtropical countries. Global incidence of dengue 
has increased dramatically in the recent years. In our study, there 
is no significant difference between mean age and sex distribution 
between three groups of dengue children. In the present study, 
male children were more affected than female which was similar 
to that of previous study [19]. This difference might be due to 
more outdoor activities of males which lead to more chances of 
daytime mosquitoes’ bite. Only serologically confirmed dengue 
cases are taken for study, out of which maximum are IgM positive 
as our study is conducted in a tertiary care center and most of the 
patients are referred from periphery hospital. Fever was the most 
Table 2a: ROC curve details of Group 1 versus Group 2
Variables AUC (%) 95% CI (%) p value Sensitivity (%) Specificity (%)
Serum bilirubin total (mg/dl) 86.6 76.5–96.6 0.000 90 62
Serum bilirubin direct (mg/dl) 78.3 65–91.6 0.000 70 73
AST (IU/L) 87.3 76.7–97.9 0.000 95 99
ALT (IU/L) 93.7 87.6–99.8 0.000 95 84
ALP (IU/L) 82.4 71.7–93.1 0.000 95 84
Clotting time (min) 70.9 56.5–85.3 0.010 70 62
PT-INR 72.2 58.3–86.1 0.006 75 65
Serum albumin (gm/dl) *11.4 0.7–22.1 0.000 25 06
RBS (mg/dl) *40.9 25.4–56.3 0.259 55 41
Serum sodium (mmol/L) *47.0 29.4–64.5 0.707 40 43
Serum potassium (mmol/L) *50.0 34.6–66.1 0.967 65 43
Serum urea (mg/dl) *41.1 24–58.1 0.270 35 46
Serum creatinine (mg/dl) *38.6 23.3–54.0 0.016 60 25
*AUC<70% is considered as not acceptable. ASTs: Aspartate transaminases, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, PT‑INR: Prothrombin time‑international 
normalized ratio, RBS: Random blood sugar, AUC: Area under the curve, CI: Confidence interval
Table 2b: ROC curve details of Group 2 versus Group 3
Variables AUC (%) 95% CI (%) p value Sensitivity (%) Specificity (%)
Serum bilirubin total (mg/dl) 93.4 86.5–100 0.000 83.3 81
Serum bilirubin direct (mg/dl) 89.9 80.1–99.8 0.000 88.9 85.7
AST (IU/L) 94.3 85.8–100 0.000 100 85
ALT (IU/L) 96.0 88.8–100 0.000 100 71
ALP (IU/L) 88.6 78.0–99.2 0.000 83.3 81
Clotting time (min) 100 100 0.000 100 100
PT-INR 72.2 58.3–86.1 0.006 100 100
Serum albumin (gm/dl) *0.3 0–1 0.000 100 100
RBS (mg/dl) *40.9 22.6–59.2 0.331 44.4 32
Serum sodium (mmol/L) *55.8 37.2–74.4 0.535 55.6 62
Serum potassium (mmol/L) *50.0 22.9–59.4 0.345 50 53
Serum urea (mg/dl) *63.5 45.5–81.5 0.151 66.7 66.7
Serum creatinine (mg/dl) *61.8 43.7–79.9 0.210 61.1 61.9
*AUC<70% is considered as not acceptable. ASTs: Aspartate transaminases, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, PT‑INR: Prothrombin time‑international 
normalized ratio, RBS: Random blood sugar, AUC: Area under the curve, CI: Confidence interval
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common symptom invariably present in all the three groups and 
this was similar to the study done in India in 2015 [19]. In our 
study, abdominal pain, tenderness, and hepatomegaly were found 
in 50% cases, which was similar to the report by other studies 
[9-12] with 36.4–96% of the cases. Among hepatic dysfunctions, 
Sr. bilirubin is raised in 34% cases similar to earlier study [19]. 
Liver damage with elevation of aminotransferase enzymes is 
a known complication of dengue infection. Hence, AST and 
ALT values measurements are mandatory to know the liver 
involvement [20]. AST levels tend to rise more than ALT levels 
in dengue infections [21,22]. The definite cause is not known, 
but it may be due to excessive release of AST from damaged 
myocytes during dengue [23]. In our study, ALT values were 
greater than AST values which were contrary to other study [24]. 
The AST levels return to normal more rapidly than ALT levels as 
AST (12.5–22 h) has a shorter half-life than ALT (32–43 h) [25]. 
As this is a tertiary care hospital-based study, maximum cases 
were referral patients from periphery hospital which in turn 
may account for the greater ALT values than AST in our study. 
Similarly, ALP levels were raised more in Groups 2 and 3 which 
were similar to previous study [25]. PT-INR and CT values were 
increased in Group 3 cases.
Laboratory parameters were taken as Score-A (Table 1c). 
However, not all the laboratory parameters were taken into 
consideration for score. We have also done CBC, but we have 
not included those parameters, as our point of interest was only 
hepatic dysfunction parameters. We have taken RBS, Sr. sodium, 
Sr. potassium, Sr. urea, Sr. creatinine, Sr. bilirubin total and direct, 
AST, ALT, ALP, Sr. albumin, PT-INR, and CT as these laboratory 
parameters affect or alter the liver functions. RBS is monitored 
as there may be hypoglycemia in hepatic pathology [26]. Low 
Sr. sodium (hyponatremia) is a known complication in liver 
disease which leads to altered sensorium or seizure [27]. Low Sr. 
potassium (hypokalemia) is noted in liver dysfunctions which in 
turn affect other systems of the body [27]. Sr. urea and creatinine 
is taken due to the chance of hepatorenal syndrome resulting in 
uremia, azotemia [28]. Sr. bilirubin total and direct, AST, ALT, 
ALP, and Sr. albumin levels were measured as these parameters 
altered most in liver dysfunctions [19-22]. CT and PT-INR were 
evaluated due to their alteration in severe hepatic dysfunction, 
whereas BT was not included as its derangement reflects platelet 
disorder, and further, we have included bleeding manifestations 
in clinical hepatic parameters [19-22,29]. Of these, only those 
parameters were considered for score whose cutoff values were 
acceptable as evidenced by AUC ≥70% in ROC curve.
In ROC curve analysis, although p value is statistically 
significant, the test is said to be acceptable only when AUC 
≥70%. In our study, RBS, Sr. sodium, Sr. potassium, Sr. urea, Sr. 
creatinine, and Sr. albumin were excluded from scoring system 
due to the fact that their cutoff values were not acceptable as 
exhibited by AUC ˂70%. Hence, these parameters were not 
included in Score-A.
We have also given points to various clinical hepatic 
manifestations based on its presence (1) or absence (0) and 
named it as Score-B (Table 1a). The variables included for score 
were vomiting, pain abdomen and/or tenderness, hepatomegaly, 
ascites, bleeding manifestations, respiratory distress, loss of 
consciousness or seizure, and shock. These specific clinical 
features were considered for score due to the fact that all these 
parameters were there in dengue classification, the WHO 
2009. We have included vomiting as it is one of the common 
symptoms in liver disease as well as in dengue. Pain abdomen 
and/or tenderness occur due to stretching of the liver capsules, a 
cardinal feature of liver involvement [30], so included in score. 
Hepatomegaly is an important sign found in liver diseases due 
to infections or inflammation [30], hence, considered for score. 
Ascites is also commonly seen in dengue with warning signs and 
other liver diseases [31]. We have taken only clinical ascites not 
the sonographically proved one as our score system is meant for 
primary health caregivers in periphery hospital as well where 
ultrasound facility is rare. Bleeding manifestations, respiratory 
distress, loss of consciousness or seizure, and shock are included 
because these are the main clinical signs and symptoms seen in 
severe dengue as well as other severe liver diseases [29-31]. We 
have not included fever in our score as it is present invariably in 
all three groups of dengue. Jaundice also not included, though it 
is a main symptom in liver diseases as sometimes it is difficult 
to appreciate in anicteric phase, so we have taken Sr. bilirubin 
Figure 2: Dengue hepatic severity score (Group 1 vs. Group 2)
Figure 3: Dengue hepatic severity score (Group 2 vs. Group 3)
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instead which is more confirmatory [20]. We have not done 
tourniquet test also as low proportion of positive tourniquet test 
seen in Indian studies may be due to the darker skin color in 
Indian children [22].
Like other studies, the current study is also not devoid of 
limitations. Since this is a cross-sectional study, level of evidence 
is low. As it is a hospital-based study in a tertiary care center 
with limited resources, its result could not be generalized. It is a 
single-center study with small sample size, so the results were not 
devoid of confounder, interactions despite our relentless efforts. 
This study was also not devoid of selection bias due to sampling 
technique and data collection method from existing records. In 
view of the above-mentioned limitations, long-term follow-up 
was required for validity of the study and test of reliability was 
needed, and therefore, in future, a larger multicenter cohort study 
is awaited to do time trend analysis to assess the prediction of 
progression from one category to other. We have planned to test 
the reliability of this score system at community level and this is 
under process.
CONCLUSION
The results of the present study conclude that DHSS could be a 
useful tool to predict and treat severity of dengue infections in 
future so that a primary health caregiver can receive the maximum 
benefit for triaging, early recognition, and prompt management 
which in turn will reduce the morbidities, mortalities, financial 
burden of the parents, and the government as well.
REFERENCES
1. World Health Organization; Dengue and Dengue Hemorrhagic Fever. 
Available from: http://www.who.int/media centre/factsheets./fs117/en. [Last 
accessed on 2013 Apr 19].
2. World Health Organization. Dengue: Guideline for Diagnosis, Treatment, 
Prevention and Control. Geneva: World Health Organization; 2009.
3. Centers for Disease Control and Prevention (CDC). Imported dengue-united 
states, 1997 and 1998. MMWR Morb Mortal Wkly Rep 2000;49:248-53.
4. Special Programme for Research, Training in Tropical Diseases, and 
World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, 
Prevention and Control. Geneva, Switzerland: World Health Organization; 
2009.
5. Gupta N, Srivastava S, Jain A, Chaturvedi UC. Dengue in India. Indian J 
Med Res 2012;136:373-390.
6. WHO. Dengue and Dengue Haemorrhagic Fever, Factsheet no 117. Geneva, 
Switzerland: World Health Organization; 2008. Available from: http://www.
who.int/me diacentre/factsheets/fs117/en.
7. Wiwanitkit V. Liver dysfunction in dengue infection, an analysis of the 
previously published Thai cases. J Ayub Med Coll Abbottabad 2007;19:10-1.
8. Soundravally R, Narayanan P, Bhat BV, Soundraragavan J, Setia S. 
Fulminant hepatic failure in an infant with severe dengue infection. Indian J 
Pediatr 2010;77:435-7.
9. Petdachai W. Hepatic dysfunction in children with dengue shock syndrome. 
Dengue Bull 2005;29:112-7.
10. Mohan B, Patwari AK, Anand VK. Hepatic dysfunction in childhood dengue 
infections. J Trop Pediatr 2000;46:40-3.
11. Wahid SF, Sanusi S, Zawawi MM, Ali RA. A comparison of the pattern of 
liver involvement in dengue haemorrhagic fever with classic dengue fever. 
Southeast Asian J Trop Med Pub Health 2000;31:259-63.
12. Itha S, Kashyap R, Krishnani N, Saraswat VA, Choudhuri G, Aggarwal R, et 
al. Profile of liver involvement in dengue virus infection. Natl Med J India 
2005;18:127-30.
13. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, 
Sukthana Y, Pukrittayakamee S. Risk factors and clinical features associated 
with severe dengue infection in adults and children during the 2001 epidemic 
in Chonburi, Thailand. Trop Med Int Health 2004;9:1022-9.
14. Huerre MR, Lan NT, Marianneau P, Hue NB, Khun H, Hung NT, et al. Liver 
histopathology and biological correlates in five cases of fatal dengue fever 
in Vietnamese children. Virchows Arch 2001;438:107-15.
15. Trung DT, Thao le TT, Hien TT, Hung NT, Vinh NN, Hien PT, et al. Liver 
involvement associated with dengue infection in adults in Vietnam. Am J 
Trop Med Hyg 2010;83:774-80.
16. Pongpan S, Wisitwong A, Tawichasri C, Patumanond J. Prognostic indicators 
for dengue infection severity. Int J Clin Pediatr 2013;2:12-8.
17. Uchadadia S, Ghodke B, Bhuta K, Kejriwal A, Ghanekar J. Degree of 
impairment of liver function in dengue fever correlates to the severity of its 
complications. MGM J Med Sci 2015;2:115-9.
18. Arya SC, Agarwal N, Parikh SC. Usefulness of detection of dengue NS1 
antigen alongside igM plus igG, and concurrent platelet enumeration during 
an outbreak. Trans R Soc Trop Med Hyg 2011;105:358-9.
19. Selvan T, Purushotham DR, Swamy N, Giridhar, Kumar M, Suresh. study of 
prevalence and hepatic dysfunction in dengue fever in children. Sch J Appl 
Med Sci 2015;3:2071-4.
20. Souza LJ, Alves JG, Nogueira RM, GicovateNeto C, Bastos DA, 
Siqueira EW, et al. Aminotransferase changes and acute hepatitis in patients 
with dengue fever: Analysis of 1,585 cases. Braz J Infect Dis 2004;8:156-63.
21. Souza LJ, GoncalvesCarnerio H, SoutoFilho JT, Souza TF, Cortes VA, 
Neto CG, et al. Hepatitis in dengue shock syndrome. Braz J Infect Dis 
2002;6:322-7.
22. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, 
Kunentrasai N, et al. Early clinical and laboratory indicators of acute dengue 
illness. J Infect Dis 1997;176:313-21.
23. Kuo CH, Tai DI, Chang-Chien CS, Lan CK, Chiou SS, Liaw YF, et al. Liver 
biochemical tests and dengue fever. Am J Trop Med Hyg 1992;47:265-70.
24. Chhina RS, Goyal O, Chhina DK, Goyal P, Kumar R, Pun S. Liver function 
tests in patients with dengue viral infection. Dengue Bull 2008;32:110-7.
25. Sedian A, Bhattarai GR, Adhikari S, Shreshta B, Sapkota A. Liver 
involvement associated with dengue infection during a major outbreak in 
central Nepal. J Adv Intern Med 2013;2:42-6.
26. Laragh JH, Ames RP. Physiology of body water and electrolytes in hepatic 
disease. Med Clin N Am 1963;47:587.
27. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver 
diseases. World J Gastroenterol 2007;13:5552-9.
28. Arky RA. Hypo glycaemia associated with liver disease and Ethanol. 
Endocrinol Metab Clin North Am 1989;18:75-90.
29. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients 
with liver disease. J Hepatol 2002;37:280-7.
30. Anand B, Krok K, Pollak E. Evaluation of hepatomegaly. First Consult. 
Available from: http://www.mdconsult.com. [Last updated 2007 Sep 19].
31. Dudley FJ. Pathophysiology of ascites formation. Gastroenterol Clin N Am 
1992;21:215-35.
Funding: Self-funded. Conflict of Interest: None Stated.
How to cite this article: Murmu SK, Mishra NR, Nayak BK. Dengue hepatic 
severity score: A glimmer to the clinician. Indian J Child Health. 2018; 
5(2):80-85.
